Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Nirsevimab was effective for the prevention of severe respiratory syncytial virus-related outcomes among infants and children in real-world clinical settings. Real-world outcomes suggest nirsevimab ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Older age, Black race, very low Child Opportunity Index, public insurance linked to lower rates of nirsevimab receipt ...

Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building ...

Pregnant individuals commonly reported hesitancy toward RSVpreF and nirsevimab, indicating the need for efforts to promote the safety and uptake of RSV immunization.

John Stewart, Director of Specialised Commissioning at NHS England said: “For babies born very prematurely, the risk of ...

Key Takeaways A new RSV antibody shot for babies could be struggling to gain tractionOnly 35% of eligible infants received nirsevimab during the 2023-24 RSV seasonAll babies younger than 8 months are ...

Thousands of premature babies in the UK can now be protected against a common winter virus which can cause a dangerous lung ...